SCOTTSDALE, AZ -- (MARKET WIRE) -- March 01, 2007 -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), announced today that as a result of ImmuneRegen's recent successful study of its immunomodulator Viprovex™, which successfully prevented adverse effects from H3N2 avian influenza, that it would study Viprovex in conjunction with Tamiflu, the FDA-approved neuraminidase inhibitor used to treat, and as a pre-exposure prophylactic, to protect against influenza.
